Silexion Therapeutics has dosed the first patient in its Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, marking a key step in patient treatment. New data shows SIL204 may enhance immune response and uses natural blood carriers for delivery, supporting systemic use. The company raised $4.8 million in cash by the end of Q3 2026 through financings, strengthening its balance sheet to support ongoing trials. Additional clinical sites in Israel and Germany are expected to join the trial soon, advancing the development of this RNA interference therapy targeting KRAS mutations in cancer.
Silexion Therapeutics' recent clinical and financial update is provided here with relevant market data for context. For readers following the health sector, 107 of 150 US health stocks on Pluang rose while 39 fell. Notable movers include The Cooper Companies Inc. at USD 63.52 (+2.14%), Takeda Pharmaceutical Company Limited at USD 21.55 (+2.04%) with 100% buy orders, and ACADIA Pharmaceuticals Inc. at USD 18.48 (+1.87%) with 98% sell orders. Data is as of Nov 13, 2026 20:42 WIB.
The Beer Institute recognized 16 outstanding professionals with its 2026 BEST IN BREW Honors, celebrating their exceptional contributions across brewing, supply chain, and leadership roles in the U.S. beer industry. This annual award highlights the d...
REalloys Inc. reported a net loss of $30.5 million in Q3 2026 but made significant progress by signing a non-binding term sheet with the U.S. Army for a heavy rare earth processing facility at Tooele Army Depot, Utah. The company is advancing its met...
Modern Mining Technology Corp. began trading on the NYSE American after raising nearly $40 million in an IPO. The company recovers valuable metals like gold, silver, and copper from electronic waste using a proprietary process, avoiding traditional m...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
